During the last session, ProKidney Corp (NASDAQ:PROK)’s traded shares were 209.37 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $4.34, reflecting an intraday gain of 16.35% or $0.61. The 52-week high for the PROK share is $4.92, that puts it down -13.36 from that peak though still a striking 89.4% gain since the share price plummeted to a 52-week low of $0.46. The company’s market capitalization is $1.27B, and the average intraday trading volume over the past 10 days was 57.5 million shares, and the average trade volume was 6.75 million shares over the past three months.
ProKidney Corp (PROK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.29. PROK has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
ProKidney Corp (NASDAQ:PROK) trade information
ProKidney Corp (PROK) registered a 16.35% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.35% in intraday trading to $4.34, hitting a weekly high. The stock’s 5-day price performance is 667.87%, and it has moved by 343.94% in 30 days. Based on these gigs, the overall price performance for the year is 156.80%. The short interest in ProKidney Corp (NASDAQ:PROK) is 16.8 million shares and it means that shorts have 32.47 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 13.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $6 respectively. As a result, PROK is trading at a discount of -38.25% off the target high and 30.88% off the low.
While earnings are projected to return 21.23% in 2025, the next five years will return -2.42% per annum.
PROK Dividends
ProKidney Corp is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ProKidney Corp (NASDAQ:PROK)’s Major holders
ProKidney Corp insiders own 30.05% of total outstanding shares while institutional holders control 41.66%, with the float percentage being 59.55%. MORGAN STANLEY is the largest shareholder of the company, while 100.0 institutions own stock in it. As of 2024-06-30, the company held over 14.45 million shares (or 19.034% of all shares), a total value of $35.54 million in shares.
The next largest institutional holding, with 9.34 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 12.306% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of ProKidney Corp (PROK) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.97 shares. This amounts to just over 2.29 percent of the company’s overall shares, with a $12.89 million market value. The same data shows that the other fund manager holds slightly less at 2.58, or about 1.99% of the stock, which is worth about $11.19 million.
